Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment

June 6, 2018
Prometic Life Science's senior director details the promising efficacy PBI-4050 alone or in combination with nintedanib demonstrated for treatment of IPF, suggesting the potential as an antifibrotic, anti-inflammatory and pro-tissue repair mechanism.

No Previous Videos

Next Video
Prometic Life Sciences 2016 Update
Prometic Life Sciences 2016 Update

Prometic Life Sciences CEO Pierre Laurin gives an end of year update for 2016.